Types Of Ovarian Carcinoma Research Articles

Phase II trial of vinblastine in previously treated patients with ovarian cancer: A southwest oncology group study

Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over 5 days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18- and 36-week durations and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.

Phase II trial of vinblastine in previously treated patients with ovarian cancer: A Southwest Oncology Group study

Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over five days at a starting dose of 1.7 mg/m 2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18 and 36 weeks duration and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.

Tumor-Associated Glycoprotein (TAG-72) in Ovarian Carcinomas Defined by Monoclonal Antibody 872.3

Murine IgG1 monoclonal antibody (MoAb) B72.3, reactive with a high molecular weight glycoprotein complex [designated tumor-associated glycoprotein-72 (TAG-72)] was shown, with the use of the avidin-biotin-complex-immunoperoxidase technique and surgically resected tissues, to be reactive with a variety of histologic tumor types. TAG-72 is expressed in at least 5% (and up to 100%) of the malignant epithelial cells in 77% (n = 52) of human primary cancers and 71% (n = 31) of metastatic ovarian cancers of the common "epithelia" histologic category. Of these, several histologic types, including serous and mucinous cystadenocarcinomas, undifferentiated carcinomas, and less common types of ovarian carcinoma, were all shown to express TAG-72. In contrast, normal ovarian tissues and 26 of 27 benign ovarian tumors of various histologic types failed to express similar levels of TAG-72. Of interest is the 1 benign tumor that demonstrated unusual glandular complexity, as well as 3 tumors designated as borderline malignancy, that contained elevated TAG-72 expression. MoAb B72.3 also was used successfully to detect ovarian carcinoma cells in 28 cytologic preparations of human serous effusions and peritoneal washings. The reactivity of MoAb B72.3 was shown to be distinct from that of MoAb OC125 and an anti-CEA MoAb B1.1. The potential applications of MoAb B72.3 in the study of human ovarian cancer cell populations, as well as in several aspects of the management of human ovarian cancer, are discussed.

Case control study of high-risk factors in ovarian carcinomas

This study has been undertaken to explore the differences between patients bearing the three most common histologic types of ovarian carcinomas and the control group. The data were collected from 723 women: 309 patients with carcinoma of the ovary (serous carcinoma-143; mucinous-35; endometrioid-131), 105 with uterine body carcinoma, and 309 cancer-free patients. The cancer-free controls were selected according to age to give a sample with a corresponding age structure of the ovarian carcinoma groups. As compared with cancer-free controls, three factors appeared significantly more often in all three types of ovarian carcinoma: (a) early menopause (under 45 years), (b) late menarche (above 14 years), and (c) fewer pregnancies. In addition, the endometrioid type of ovarian carcinoma showed significantly higher rates of: (a) never-pregnant women, (b) nulliparity, (c) hypertension, and (d) overweight. The results of this study suggest that there is a poor functional state of the ovary enabling the development of carcinoma of any histologic kind. The differences between serous and endometrioid ovarian carcinoma and the similarity of the latter to uterine body carcinoma suggest that there are other factors affecting the development of ovarian carcinoma of the endometrioid type but not influencing the serous one.

Fine-needle aspiration biopsy in diagnosis, and classification of ovarian carcinoma.

The authors assess the value of fine-needle aspiration biopsy for determining malignancy and the type of ovarian carcinoma. Smears of fine-needle biopsy specimens from 80 cases of palpable ovarian tumors were examined for malignancy. The cases were followed-up to a definite histologic diagnosis or a final clinical diagnosis. The diagnostic accuracy of the method was 93–95%. The possibility of classifying ovarian carcinoma with fine-needle aspiration biopsy specimens was estimated in 52 cases of ovarian carcinoma. Subsequent operation and histologic examination showed good agreement between the cytologic and the histologic diagnoses.

Unilateral carcinoma arising in bilateral ovarian endometriosis

T H E E c TO Y I c location of endometrial tiSsue imposes no barrier against malignant transformation of either its glandular or stromal comp0nents.l This is evident from the numerous cases of carcinoma arising in endometriosis reported2 since Sampson’s initial description of this type of ovarian carcinoma.3 Two cases of bilateral ovarian endometriosis with unilateral malignant transformation are reported presently, emphasizing the variable neoplastic tendency in this location of the primary disease process.

Long-term survival in disseminated ovarian carcinoma

Fourteen patients who survived more than 5 years after disseminated ovarian carcinoma had been proved have been analyzed for factors that may have prolonged survival. Factors surveyed included treatment, histological grade and tumor type, age, marital status, and parity of patients. Chemotherapy appeared ineffective. Age, marital status, and parity were not considered significant. Surgery plus irradiation sometimes was effective, notably in the dysgerminoma. Low tumor grade significantly influenced survival in serous but not in endometrioid and mucinous carcinomas. In these, tumor type regardless of grade seemed more important. Intrinsic aspects of host-tumor relationships, possibly affecting growth activity, were implicated in the long survival times of patients with granulosa cell carcinoma, mesometanephroma, and the rare malignant mesothelioma. It is suggested that histologic types of ovarian carcinoma should be considered by graded and staged groups in the evaluation of therapeutic results.